Semaglutide vs Tirzepatide vs Retatrutide: Research Comparison

Semaglutide, tirzepatide, and retatrutide are often grouped together in metabolic-research catalogs, but they are distinct compounds with different receptor profiles. Semaglutide is GLP-1 selective, tirzepatide combines GIP and GLP-1 receptor activity, and retatrutide has been studied across GIP, GLP-1, and glucagon receptors.

Semaglutide vs tirzepatide vs retatrutide at a glance

Semaglutide: a GLP-1 receptor-focused analogue

Semaglutide is a modified GLP-1 analogue studied through the GLP-1 receptor pathway. Its sequence and chemical modifications distinguish it from endogenous GLP-1 and from the multi-receptor compounds in this comparison. At catalog level, “GLP-1 receptor agonist” identifies the principal receptor system associated with the compound; it does not describe a vial’s analytical quality or make two products experimentally equivalent.

A semaglutide listing should therefore be read in two layers: the compound identity and receptor profile provide the research context, while the product page supplies the labeled amount, format, price, image, documentation language, and current stock state.

Tirzepatide: one peptide with two-receptor activity

Tirzepatide is engineered as a dual GIP and GLP-1 receptor agonist. Primary laboratory research has described an imbalanced signalling profile, with different behaviour at the two receptor systems. “Dual agonist” refers to the target profile of a single engineered peptide. It should not be interpreted as two separate peptides mixed in one vial.

This distinction matters when comparing category listings. A product may sit beside semaglutide because both involve GLP-1 receptor research, but tirzepatide’s GIP receptor activity means the compounds should not be treated as interchangeable controls or assumed to share the same analytical behaviour.

Retatrutide: a three-receptor research profile

Retatrutide, also identified in the literature as LY3437943, has been investigated as an agonist at GIP, GLP-1, and glucagon receptors. The glucagon-receptor component is the clearest receptor-level distinction between retatrutide and tirzepatide. As with the other compounds, the receptor designation describes the molecule’s research profile—not a claim about the purity, concentration, or suitability of a particular vial.

ELMNTPEP lists retatrutide in 10mg and 20mg labeled amounts. Those are two product strengths of the same named compound, not two different receptor profiles. The Retatrutide Starter Kit is a separate multi-item listing whose contents are stated directly on its product page.

Why receptor count does not rank the compounds

It is tempting to treat one, two, and three receptors as a simple progression. That shortcut leaves out the details that determine whether a comparison is scientifically useful. Sequence, receptor potency, signalling bias, assay design, model system, controls, handling history, and analytical verification all matter. More named receptors does not automatically mean higher quality or greater relevance to a specific research question.

Direct comparison also requires care. Results from separate papers can differ because of experimental systems, endpoints, concentrations, observation periods, and statistical methods. A catalog overview can clarify compound identity and receptor profile, but it cannot replace study-specific methods or a review of the original literature.

What to compare on the three product listings

Price and vial size are purchasing fields, not evidence that two compounds are experimentally equivalent. Likewise, a shared “GLP” category is useful for navigation but does not erase compound-specific differences.

Documentation and handling belong in the comparison

A strong product comparison extends beyond the receptor table. Read the peptide testing documentation guide for a practical explanation of identity, purity, labeled amount, batch identifiers, and method context. After receipt, use the research peptide storage and handling checklist to plan chain-of-custody records, storage-state controls, light and moisture protection, and quarantine decisions.

Testing documentation is available. Certificates of analysis will be posted to the site as they become available.

Primary research references

• Jensen et al. (2017) examined the absorption, metabolism, and excretion of the GLP-1 analogue semaglutide.
• Willard et al. (2020) characterized tirzepatide as an imbalanced and biased dual GIP/GLP-1 receptor agonist.
• Rosenstock et al. (2023) described retatrutide as a GIP, GLP-1, and glucagon receptor agonist in a phase 2 study.

Explore every ELMNTPEP research comparison →

Go deeper: Read the Retatrutide research guide for receptor-assay, structural, evidence-layer, and analytical context specific to LY3437943.

Research use notice: This comparison provides educational catalog context, not medical, administration, or dosing guidance. ELMNTPEP products are intended for laboratory research use only and are not for human or veterinary consumption.